Theragenics Corporation

Theragenics Corporation is a United States-based specialty medical device and radioisotope company headquartered in Buford, Georgia. Founded in 1981 by a group of physicists from the Georgia Institute of Technology, the company has spent more than four decades developing and manufacturing radiological pharmaceuticals and devices used in cancer care. Its core business is the production of medical radioisotopes and brachytherapy technologies, particularly low-dose-rate (LDR) brachytherapy seeds used to treat prostate cancer and other conditions. Theragenics describes itself as a global partner for radioisotope contract manufacturing (CMO), brachytherapy products, and solutions, serving physicians, providers, and patients in more than 40 countries. Theragenics operates a 134,000-square-foot radioisotope production facility in Buford, Georgia, and reports access to 14 cyclotrons that enable a broad range of isotope production. Its product portfolio includes brachytherapy seeds and related delivery solutions, with flagship offerings such as TheraSeed and AgX100. The company also supplies radioisotopes and radiopharmaceuticals for applications in interventional radiology, interventional cardiology, and vascular surgery. Its brands and sister companies include Galt Medical, Galt Medical OEM, and Arrotek, extending its reach into medical device design and contract manufacturing. Historically, Theragenics was a publicly traded company before being acquired by Juniper Investment Company and taken private in the 2010s. During that decade it also acquired multiple brachytherapy suppliers, expanded market access, received FDA 510(k) clearance for AgX100, and acquired Arrotek Medical, a full-service medical device design consultancy based in Sligo, Ireland. In the 2020s, the company expanded its operations to offer contract manufacturing services supporting radiopharmaceutical production and delivery, and celebrated its 40th anniversary. Theragenics positions itself around precision, quality, and responsibility, emphasizing that it does not simply supply products but supports patient treatments. Its mission is to transform healthcare globally through disruptive technologies using a patient-friendly, targeted approach, and its vision is to improve patient outcomes with every product. The company remains privately held under Juniper Investment Company and continues to operate as a specialty medical device and radioisotope manufacturer.

Theragenics Corporation was founded in 1981 by a group of physicists from the Georgia Institute of Technology who set out to create innovative radiological pharmaceuticals and devices to combat cancer. From its early years, the company focused on radioisotope production, building deep expertise that would become the foundation of its cancer care business. In the 2000s, Theragenics launched TheraSeed direct to customers and expanded its product line with the acquisition of an existing Iodine-125 prostate business. This purchase enabled the company to supply both Palladium-103 and Iodine-125 brachytherapy seeds, strengthening its position in the prostate brachytherapy market. During the 2010s, Theragenics underwent significant changes. It acquired multiple brachytherapy suppliers, expanding market access. It received FDA 510(k) clearance for AgX100. Juniper Investment Company acquired Theragenics and took the organization private. The company also acquired Arrotek Medical, a full-service medical device design consultancy, expanding operations into Sligo, Ireland. These moves broadened Theragenics beyond brachytherapy into medical device design and contract manufacturing. In the 2020s, Theragenics expanded its operations to offer contract manufacturing services to support radiopharmaceutical production and delivery. The company celebrated its 40th anniversary, continuing to build on its history of advancing patient care. As of the early 2020s, Theragenics operates a 134,000-square-foot radioisotope production facility in Buford, Georgia, with access to 14 cyclotrons for isotope production. Its products have been used in more than 271,000 treatments with its brachytherapy seeds and solutions, and physicians in more than 40 countries trust its products. The company remains privately held under Juniper Investment Company and continues to develop and produce life-saving radioisotopes and medical devices.

• 2021

  Celebrates 40th anniversary.

• 2020

  Operations expand to offer contract manufacturing services to support radiopharmaceutical production and delivery.

• 2010

  Acquires multiple brachytherapy suppliers, expanding market access.

• 2010

  AgX100 receives FDA 510(k) clearance.

• 2010

  Juniper Investment Company acquires Theragenics and takes the organization private.

• 2010

  Acquires Arrotek Medical, expanding operations into Sligo, Ireland.

• 2000

  Launches TheraSeed direct to customers and expands product line with acquisition of an Iodine-125 prostate business.

• 1981

  Founded by a group of physicists from Georgia Institute of Technology.

A global specialty medical device company dedicated to empowering the fight against cancer through precision radioisotope production and brachytherapy technologies.

• TheraSeed

  Brachytherapy seed product launched direct to customers in the 2000s.

• AgX100

  Brachytherapy product that received FDA 510(k) clearance in the 2010s.

• Radioisotopes & Radiopharmaceuticals

  Medical radioisotopes produced at a 134,000 sq ft facility with 14 cyclotrons.

• Brachytherapy Seeds & Solutions

  LDR brachytherapy seeds and solutions used in over 271,000 treatments.

1. 1Theragenics – A global specialty medical device companytheragenics.com
2. 2Our History – Theragenicstheragenics.com
3. 3About Us – Theragenicstheragenics.com
4. 4Careers – Theragenicstheragenics.com
5. 5Theragenics Corporation (United States) – Wikidatawikidata.org